1. Nephrotic syndrome with Minimal Change Disease and Atopy in NorthAfrican adults.
- Author
-
Hadhri A, Mrabet S, Ben Aicha N, Fradi A, Azzabi A, Sahtout W, Boukadida R, Guedri Y, Zellama D, Abdessaied N, Ben Saad H, and Achour A
- Subjects
- Male, Humans, Adult, Young Adult, Middle Aged, Retrospective Studies, Immunoglobulin E, Nephrotic Syndrome diagnosis, Nephrotic Syndrome epidemiology, Nephrotic Syndrome therapy, Nephrosis, Lipoid diagnosis, Nephrosis, Lipoid epidemiology, Hypersensitivity
- Abstract
Introduction: In adults, minimal change disease (MCD) accounts for 15 to 25% of nephrotic syndrome (NS). Numerous reports have suggested a link between NS and atopy. However, data on treatment and prognosis of NS associated with allergy are limited., Aim: To examine the presenting characteristics, treatments and outcomes of adults with allergic MCD in a North African center., Methods: This was an observational study using retrospectively collected data. Patients were recruited from the Nephrology department of Sahloul Hospital (Sousse, Tunisia) from January 2006 to December 2020. Adults with a biopsy proved MCD, which was associated with atopy, were included., Results: Fifteen patients (eight males, age mean±SD: 34±13 years) were included. High eosinophil and immunoglobulin E (IgE) levels were noted in three and twelve patients respectively. The IgE mean level at the initial presentation was 1431 IU/ml. Allergic skin tests were positive in nine patients. All patients were treated with corticosteroids, five had anti-histamine therapy and five had hyposensitization therapy, which was successful in two patients. Thirteen patients had relapsed during follow-up. Mean eosinophil level was significantly higher in patients with frequent relapses compared to those with infrequent relapses (5415/mm³ vs. 239.12/mm³, respectively, p=0.022). Two patients had progressed to chronic renal failure., Conclusion: It is important to search for atopic disorders in patients with MCD to better control this disease and use specific treatments. However, the efficacy of anti-allergic therapies has to be proven.
- Published
- 2023